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Summary
  A vast amount of data shows that angiogenesis has a pivot-
al role in tumor growth, progression, invasiveness and metas-
tasis. This is a complex process involving essential signaling 
pathways such as vascular endothelial growth factor (VEGF) 
and Notch in vasculature, as well as additional players such 
as bone marrow-derived endothelial progenitor cells. Prima-
ry tumor cells, stromal cells and cancer stem cells strongly 
influence vessel growth in tumors. Better understanding of 
the role of the different pathways and the crosstalk between 
different cells during tumor angiogenesis are crucial factors 
for developing more effective anticancer therapies. Targeting 
angiogenic factors from the VEGF family has become an ef-
fective strategy to inhibit tumor growth and so far the most 
successful results are seen in metastatic colorectal cancer 
(CRC), renal cell carcinoma (RCC) and non-small cell lung 
cancer (NSCLL). Despite the initial enthusiasm, the angio-
genesis inhibitors showed only moderate survival benefit as 
monotherapy, along with a high cost and many side effects. 
Obviously, other important pathways may affect the angio-
genic switch, among them Notch signaling pathway attract-
ed a large interest because its ubiquitous role in carcinogen-
esis and angiogenesis. Herein we present the basics for VEGF 
and Notch signaling pathways and current advances of tar-
geting them in antiangiogenic, antitumor therapy.
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Introduction
Angiogenesis is involved in many physiolog-
ical processes, but also is a hallmark in the pa-
thology of many diseases (cancer, ischemia, ath-
erosclerosis, inflammatory diseases), in wound 
healing and in tissue regeneration. It is of crucial 
importance for the survival of cancer cells, for 
tumor growth and spreading [1]. Angiogenesis is 
a complex process, tightly regulated at molecu-
lar level by involving growth factors, receptors, 
extracellular matrix (ECM) proteins and the hu-
moral factors [2]. Well defined types of cells par-
ticipate in the process of angiogenesis and most 
of them have specific molecular markers. The pri-
mary driver of angiogenesis is hypoxia, leading 
to secretion of VEGF and other pro-angiogenic 
molecules from hypoxic cells [3]. The proper an-
giogenesis is a stepwise process [4], beginning 
with degradation of the ECM and sprouting of the 
endothelial cells (expressing VEGF receptors) to-
ward the gradient of VEGF. The next step is differ-
entiation of the endothelial cells into several cell 
types (tip, stalk and tube cells) with subsequent 
tube formation and maturation [5]. The tip cells 
(expressing DLL4) are non-proliferative cells, lo-
cated at the top of the new vessels and account 
for the direction of the new vessel. Stalk cells 
(expressing Notch-1) are highly proliferative and 
form the trunk of the new vessels. The tube cells 
are non-proliferating, lumen containing cells that 
shape the final appearance of the vessels. Special-
ized support cell type, the pericytes expressing 
platelet-derived growth factor receptor beta (PDG-
FRβ) and alpha-smooth-muscle actin (α-SMA), 
cover the capillaries by coupling to endothelial 
cells with direct cell-to-cell and gap junctional 
contacts [6]. Other cells, mentioned later on, from 
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circulation and from the tumor environment con-
tribute to tumor angiogenesis as well.
VEGF signaling in angiogenesis
VEGF family members are the most impor-
tant factors that induce angiogenesis [7]. A num-
ber of essential properties are attributed to VEGF 
with direct effect on promoting angiogenesis. 
First, it is its his proliferative effect on target en-
dothelial cells, which start growing under its in-
fluence, increasing their survival and decreasing 
the apoptotic rate. Second, it enhances vascular 
permeability which is connected to extravasation 
and migration of different cells from/into circula-
tion. Inducing vasodilatation is another property 
of VEGF in regard to its potent angiogenic effect. 
VEGF family includes VEGF A, B, C, D, and pla-
cental growth factor (PIGF).  VEGF-A is the best 
characterized for its role in angiogenesis; it acts 
through tyrosine kinase VEGF receptor 2 (VEG-
FR2), whereas the role of VEGF receptor 1 (VEG-
FR1) in angiogenesis is still vague. Most cancers 
exhibit a high expression of VEGF [8]. Immunohis-
tochemical analysis for VEGF expression in CRC 
(compilation data from 17 independent studies) 
showed association of the degree of its immuno-
reactivity with poor survival [9]. Increased expres-
sion of VEGF has been found in NSCLC [10] and 
RCC [11], and in many instances it is associated 
with increased risk of recurrence, metastasis, and 
death. Preclinical studies provided evidence that 
angiogenesis also plays a central role in breast 
cancer carcinogenesis and metastatic potential. A 
variety of pathophysiological circumstances can 
induce VEGF expression. One of the most impor-
tant is low oxygen tension which triggers hypoxic 
response by mediation of hypoxia-inducible fac-
tor 1α (HIF1α) [12]. Paracrine or autocrine release 
of some major growth factors such as epidermal 
growth factor (EGF), transforming growth fac-
tor (TGF) α and β, platelet-derived growth factor 
(PDGF), insulin-like growth factor 1 (ILGF-1) and 
fibroblast growth factor (FGF) upregulate VEGF 
levels as well [13]. Somatic genetic mutations 
could also induce activation of VEGF [14]. All 
the abovementioned events show off the central 
role of angiogenesis in tumor development and 
spreading. Tumors over 2 mm3 are unlikely to sur-
vive without proper vascularisation. In contrast to 
the normal vessels, tumor vessels have a different 
morphology, characterized by higher leakage, ar-
bitrary branching and blind ending.
VEGF in tumors can act through three mech-
anisms. Tumor cells produce VEGF, which binds 
VEGFR2 on the endothelial cells (paracrine mech-
anism). However, elevated levels of VEGF are not 
useful as predictive markers, because various 
cells, such as platelets, muscle cells and tumor 
stromal cells, also produce it [15]. Some tumors 
express both VEGF and VEGFR2 (autocrine mech-
anism). In some cases, like in breast cancer, VEGF 
receptor is expressed within the cells (intracrine 
mechanism). VEGF can also bind neuropilin re-
ceptor (NRP), which lacks tyrosine kinase activity 
and may serve as co-receptor of VEGFR2, account-
ing for the regulation of angiogenesis [16]. Bind-
ing of VEGF-C to VEGFR3 promotes lymphangi-
ogenesis. There are different signaling pathways 
after binding VEGF with its receptor, which pro-
mote migration, survival and proliferation of the 
endothelial cells. MAPK pathway is related to 
DNA synthesis and the cell growth, whereas PI3K 
pathway promotes their survival. The activation 
of src leads to cell migration [17]. 
Folkman first proposed that targeting the 
vessels formation in the tumor can prevent its 
growth [18]. During the past decades, intensive 
research led to the creation of a new type of ther-
apy for cancer, aiming at the disruption of tumor 
vasculature by targeting the VEGF family mem-
bers (Table 1). Bevacizumab is a monoclonal an-
tibody against VEGF, whereas Sorafenib and Su-
nitinib are inhibitors of tyrosine kinase receptors 
(TKRs). Bevacizumab is effective in advanced CRC, 
especially in combination with the conventional 
chemotherapy [30,31], Sorafenib is approved as 
monotherapy of hepatocellular carcinoma and 
Sunitinib for metastatic RCC. The most encourag-
ing results have been obtained for Bevacizumab 
in the treatment of metastatic CRC, RCC, breast 
cancer, and NSCLC patients.
The antitumor activity of Bevacizumab has 
been extensively demonstrated in preclinical stud-
ies in several tumor models. These studies found 
that single-agent therapy with bevacizumab or its 
murine equivalent resulted in tumor growth in-
hibition of a number of human tumor cell lines 
xenografted in rodent models, irrespective of the 
route of administration or tumor location. The as-
sayed tumor types included rhabdomyosarcoma, 
glioblastoma, leiomyosarcoma, colon adenocarci-
noma, hepatoblastoma, neuroblastoma, Wilms’tu-
mor, and ovarian, prostate or breast carcinomas 
[32]. Studies with in vitro cell lines did not reveal 
a direct effect of the antibody on the growth of 
tumor cells, suggesting that tumor suppression 
is mediated through inhibition of neovasculariza-
tion. Several studies have shown that anti-VEGF 
therapy also prevented the growth of tumor cells 
at metastatic sites [33].
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However, the initial enthusiasm regarding 
anti-VEGF signaling therapy was cooled by sub-
sequent trials, which could not confirm benefit of 
angiogenesis inhibitors as monotherapy. There 
are several problems that need to be solved. Dur-
ing treatment, many patients become resistant 
to antiangiogenic drugs, while no useful clinical 
marker exists that can predict which individuals 
will benefit better from treatment. Besides, an-
tiangiogenic agents are expensive and have toxic 
side effects [17]. 
The key to these questions is a more thor-
ough understanding of the mechanism of tumor 
angiogenesis, accounting for other angiogenic 
pathways. Among them, Notch signaling is the 
best candidate because of its ubiquitous role in 
cell patterning and differentiation.
 
Notch/Delta-like ligand 4 (Dll4) signal-
ing in carcinogenesis and angiogenesis 
The Notch family includes 4 receptors (Notch 
1-4) and 5 ligands (Jagged 1, 2 and Delta-like (Dll 
1,3,4) [34]. Notch receptors are single transmem-
brane proteins located on the cell surface, which 
interact with ligands expressed on the adjacent 
cells. This leads to splitting of the receptor by 
TACE and γ-secretase and subsequent transloca-
tion of its intracellular portion (NICD) into the 
nucleus. The subsequent interaction with RBP-
Jk/CBF-1 protein results in expression of genes 
normally silent in the absence of Notch signal 
such as basic helix-loop-helix genes Hes 1,5,7 
and Hesr/Hey 1,2,L. These are regulatory genes 
involved in cell differentiation and their expres-
sion is associated with uncontrolled prolifera-
tion of tumor cells [35]. Notch mutations have 
been found in approximately 50% of the cases 
of T-cell acute lymphoblastic leukemia (T-ALL) 
[36]. High expression of Jagged-1 and Notch-1 has 
been found in breast cancer [35], RCC [37], blad-
der cancer [38], pancreatic cancer [39] and meta-
static prostate cancer [40]. Approximately 4.7% of 
all solid tumors bear Notch-1 mutations, whereas 
Notch-2 and -3 are affected in 1.5 and 1.3%, re-
Table 1. Anti-VEGF signaling therapy in clinical trials
Targeted factor Agent Activity Clinical trials
VEGF Bevacizumab (Avastin); Genentech, 
South San Francisco, CA; www.
genentech.com) 
Monoclonal antibody - 
neutralizes the biologically 
active forms of VEGF that 
interact with VEGF recep-
tors 1 and 2
Phase II and III trials in, RCC, 
breast cancer, Kaposi’s sarcoma, 
pancreatic cancer, ovarian can-
cer, lymphoma, myeloma, mel-
anoma, head and neck cancer, 
leukemia, liver cancer, sarcoma, 
mesothelioma, and lung cancer 
[19,20]
VEGF VEGF-Trap (Aventis and Regen-
eron Pharmaceuticals, Tarrytown, 
NY www.regeneron.com) 
Derivative of VEGFR1, 
comprising portions of the 
extracellular domains of 
both VEGFR1 and VEGFR2
Phase I trial in patients with 
solid
tumors and non-Hodgkin’s lym-
phomas [21]
VEGF receptors and 
other tyrosine kinases
Sorafenib (BAY 43-9006, Bayer 
Pharmaceuticals Corporation, 
Leverkusen, Germany, www.phar-
ma.bayer.com, and Onyx Phar-
maceuticals, Inc., Emerville,CA, 
www.onyx-pharm.com ) 
Targets several receptor 
tyrosine kinases involved 
in neovascularization
Phase I study in advanced
refractory solid tumors [22];
Phase III study in patients with 
RCC [23]
VEGFR tyrosine 
kinases
Vatalanib PTK787/ZK22258, No-
vartis Pharma AG, Basel, Switzer-
land, www.novartis.com, co-de-
veloped with Schering AG, Berlin, 
www.schering.de 
Inhibits all known VEGFR 
tyrosine kinases
Phase I/II study in patients with 
recurrent glioblastoma multi-
forme [24];
Phase III trial in patients with 
newly diagnosed or relapsed 
advanced stage CRC [25].
VEGFR2-TIE2 
tyrosine kinases
Regorafenib (BAY 73-4506, com-
mercial name Stivarga, Bayer)
Multi-kinase inhibitor Phase III trial in metastatic CRC 
[26]
Angiogenic receptors Sutent (Sunitinib malate), (SU11248
Pfizer, Inc., New York, NY, www.
pfizer.com)
Inhibits the tyrosine kinase 
activity of a number of re-
ceptors including PDGFR, 
VEGFR2, Flt-3, and c-Kit
Phase II clinical trial involving 
CRC patients [27];
Phase II clinical trials in pa-
tients with previously treated 
metastatic breast cancer and in 
patients with unresectable neu-
roendocrine tumors [28,29]
CRC: colorectal cancer, RCC: reual cell carcinoma
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spectively. Notch-1 mutations are more frequent 
in squamous cell lung cancer and breast cancer 
and range between 5 and 15% [41]. Notch sign-
aling is essential for the colonic cell prolifera-
tion and differentiation and also plays a role in 
colonic carcinogenesis. A striking feature of the 
human CRC is the absence of goblet cells and the 
resemblance to the colonic stem cells, located at 
the base of the crypts. These unique, self-renew-
ing cells are undifferentiated and can produce all 
differentiated cells in the crypts. This process is 
regulated by Notch receptors [41]. Reedijk and 
colleagues reported an elevated expression of Jag-
ged-2 and Notch-1 in cases of CRC and concluded 
that CRC cells resemble the crypt cells. In a co-
hort of 60 CRC samples, Veenendaal et al. found 
a high expression of Notch [42]. The final step of 
the activation of Notch pathway is the expression 
of HES1, which can be used as a surrogate marker 
instead of Notch. It was also found that HES1 is 
expressed in all cases of CRC, but did not correlate 
with prognosis in a series of 130 cases. It results 
in suppression of cyclin-dependent kinase (CDK) 
inhibitors p27 and p57, with subsequent stimu-
lation of cell proliferation and suppression of cell 
differentiation in the colon [43].
Several authors have demonstrated the dual 
role of Notch signaling in carcinogenesis [44-47]. 
Depending on the cellular context, it may act as 
oncogene or as tumor suppressor. Notch acts as 
oncogene in sporadic colon cancer [43], T-acute 
lymphoblastic leukemia and breast cancer [47], 
prostatic [40], bladder [38] and pancreatic cancer 
[39], but as a tumor suppressor in skin cancer, 
cervical cancer and Ewing’s sarcoma [44,46,48], 
B-cell acute lymphoblastic leukemia, chronic my-
elomonocytic leukemia [45], and hepatocellular 
carcinoma [49]. Better understanding of this dual 
role of Notch, depending on cellular context and 
the elucidation of crosstalk between Notch and 
the other signaling pathways is of a paramount 
importance for developing of new therapies and 
also for understanding all possible consequences 
of Notch inhibition.
Of note, Notch signaling plays a significant 
regulatory role in angiogenesis, of which Notch1 
receptors, Dll4 and Jagged1 ligands are the best 
studied. Notch-1 receptor plays an important role 
in endothelial cell differentiation [50]. In response 
to VEGF, tip cells express a large amount of Dll4, 
which binds Notch-1 in the stalk cells, leading to 
downregulation of VEGF receptors with subse-
quent inhibition of sprout formation. Jagged-1 is 
an antagonist of Dll4 and promotes angiogenesis 
[51]. The role of Notch-1 and Dll4 in tumor angi-
ogenesis is of particular interest. Dll4 has shown 
strong expression in endothelial cells of diverse 
solid tumors [52,53]. 
Regulation of the Notch receptors is of par-
amount importance since they are involved in 
cell fate, differentiation and proliferation through 
cell-to-cell interplay, thus it is obvious that they 
regulate the complex tumor-stromal-endotheli-
al cells interactions. The different expression of 
Fringe genes (Lfng, Mfng, Rfng) secures the spec-
ificity of these interactions [43]. Glycosyltrans-
ferase or Fringe can modify Notch in the Golgi 
apparatus. Delta ligands prefer Fringe-modified 
Notch, whereas Jagged prefer unmodified Notch. 
This results in different activation of Notch at the 
border of Fringe-expressing and non-expressing 
cells [34].
Despite of endogenous Notch regulation, 
the DLL4/Notch signaling can be targeted in 
anticancer treatment. Its ubiquitous role in car-
cinogenesis and tumor angiogenesis makes it a 
challenging target. Unlike the VEGF antibodies, 
the treatment with Dll4 antibodies increases the 
vascularisation of the tumor. However, the new 
vessels are abnormal with increased leakage, hy-
Table 2. Anti-DLL4/Notch signaling therapy in clinical trials
Targeted factor Agent Activity Clinical trials
DLL4 Demcizumab (OMP-21M18; On-
coMed Pharmaceuticals)
Humanized monoclonal 
antibody that inhibits 
DLL4 in the Notch signal-
ing pathway
Phase I trials in advanced pan-
creatic cancer patients;
Phase I trials in advanced 
NSCLC patients [http://oncozine.
com/profiles/blogs/clinical-data-
on-oncomed-s-anti-notch2-3-
and-demcizumab-programs] 
Notch Gamma-secretase inhibitor 
RO4929097 (National Cancer 
Institute)
Oral small molecule 
inhibitor of gamma-secre-
tase, blocks the processing 
(activation) of Notch
Phase I/II trials in children with 
relapsed/refractory solid or CNS 
tumors, lymphoma, or T-Cell 
leukemia [54-56]
NSCLC: non small cell lung cancer, CNS: central nervous system
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persprouting, loss of organization and impaired 
tube formation, which leads to hypoxia and tumor 
shrinkage. There are reports suggesting benefi-
cial effect in tumors resistant to VEGF antibodies. 
Similar to VEGF antibodies, improved efficacy of 
Dll4 antibodies was observed when they are com-
bined with chemo- and radiotherapy [53]. Moreo-
ver, the simultaneous administration of VEGF and 
Dll4 antibodies seems to be more effective [54,55]. 
The therapy against DLL4/Notch signaling in tu-
mors is still in its infancy (Table 2).
The exact mechanism of action of anti-DLL4/
Notch therapy is still unknown. Yamanda and 
colleagues, suggest a possible role of VEGF-Dll4-
Ephrins axis. Ephrins are tyrosine kinase receptors 
(A and B) with two ligands – Ephrin A and B. They 
found that Dll4 blockade suppresses ephrinB2 ex-
pression in tumors. On other hand, Dll4 antibod-
ies and soluble ephrinB2 lead to suppression of 
tumor growth, suggesting they are antagonists. 
In addition, the knockdown of ephrinB2 mimicked 
the effect of Dll4 [38]. 
Before introducing anti-Notch therapy there 
are several questions to be answered: 
• Notch may act not only as an oncogene, but 
also as a tumor suppressor, probably depend-
ing on the cellular environment and interac-
tion with other signaling pathways [32, 39]. 
• The exact mechanism of action is still elusive.
• Notch signals play an important role in T-cell 
differentiation. Although they are over-ex-
pressed in the tumor vessels, they also can be 
found in smaller extent in arterioles and the 
gastrointestinal tract. The non-specific inhibi-
tion of Notch pathways via γ-secretase inhib-
itors shows beneficial effect in the treatment 
of neuroblastoma, but is accompanied with 
gastrointestinal adverse effects [12]. These ef-
fects are not observed in the treatment with 
Dll4 antibodies, but Dll4 can induce vascular 
neoplasms, atrophy of the thymus and subcu-
taneous tumors [12,39]. 
• From the therapeutic standpoint, it is impor-
tant to be proved which type of tumors will 
benefit most from such treatment and to val-
idate the most appropriate combination and 
dosage regimen [40].
Circulating bone marrow cells in angi-
ogenesis
A large number of bone marrow cells were 
found in circulating blood with a possible influ-
ence on angiogenesis. They are mainly hemato-
poietic cells (CD45+) such as monocytes myeloid 
cells, neutrophils, macrophages, but also CD45- 
endothelial progenitor cells (EPCs). First discov-
ered by Asahara in 1997, they were found to play 
a role in vascular repair in cases of myocardial in-
farction, limb ischemia, atherosclerosis, but also 
in ocular and tumor angiogenesis [41]. Although 
the phenotype of EPCs is still under investigation, 
in vivo they are characterized as CD34+, CD133+, 
CD45-, VEGRF-2+, but their isolation from the 
blood is still problematic [42]. They are mobilized 
from the bone marrow in response to tumor cy-
tokines, including VEGF and through the vessels 
they are recruited into the tumor with incorpora-
tion into the sprouting vessels [43].
Experimental evidence showed that inocula-
tion of only 12% EPCs led to progression of mi-
croscopic metastatic lesions to macroscopic ones 
[44]. Treatment with vascular disruptive agents 
leads to increase of their number and infiltration 
of the periphery of the tumor, which results in a 
rapid tumor progression [45]. Firstly, this effect is 
described with administration of maximal doses 
of cyclophosphamide. These observations are the 
rationale for the so-called metronomic therapy 
– regular administration of low doses of chemo-
therapeutic agents. It seems to prevent recruit-
ment of the EPCs and their differentiation during 
angiogenesis [46].
EPCs represent a promising novel target for 
anticancer therapy. The precise understanding of 
their activation, mobilization and recruitment in 
the tumor vessels is of paramount importance.
Cancer stem cells (CSCs) and angiogen-
ic pathways
The heterogeneity of tumor cells is well-
known, which is usually explained by their ge-
netic instability. In relation to colon cancer – and 
according to the cancer stem cell theory - the tu-
mor originates from colonic undifferentiated and 
multipotent stem cells at the base of the colonic 
crypts as a result of accumulated genetic and epi-
genetic changes. The subsequent dysregulation of 
Wnt, Notch, Hedgehog and TGF-β signaling path-
ways transforms CSC into colonic cancer stem cell 
(CCSC). CSCs are CD133+ and CD44+ positive and 
have been found in CRC. Moreover, when they 
were transferred into mice they were able to pro-
duce a tumor with identical phenotype [47-50]. It 
has been reported that Notch signaling prevents 
apoptosis of CSCs and is 10-30 fold higher in them 
in comparison to the other cell types [51]. A recent 
work of Lu et al., demonstrated that endothelial 
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cells are also involved in promoting the CSCs by 
secreting soluble Notch ligand Jagged 1 [52].
It is thought, that conventional chemother-
apy does not affect them in contrast to other tu-
mor cells. That led to the hypothesis that they 
are responsible for the resistance to treatment 
and recurrences. This population has a high ex-
pression of VEGF, which suggests possible effect 
of anti-VEGF antibodies. A possible practical im-
plication is that the combination of metronomic 
chemotherapy and anti-VEGF antibodies can be a 
more effective treatment [53].
In conclusion, tumor growth results from tu-
mor angiogenesis. A comprehensive study of an-
giogenic signaling pathways and their complex 
orchestration in tumor cell environment, taking 
into account the effects of endothelial progenitor 
and stem cells, will give the most accurate infor-
mation to adequately influence tumor growth.
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